GMP – Page 465 – Pharma.Tips

Drop Test Failure after valve supplier change: FDA/MHRA inspection-ready documentation

Managing Drop Test Failures Following a Valve Supplier Change In the dynamic world of pharmaceutical manufacturing, change is a constant theme. However, changes such as a supplier switch, especially for…

API microbial limit failure during routine release testing: root cause analysis (process vs lab) with CAPA effectiveness checks

Root Cause Analysis of Microbial Limit Failures in API Release Testing In pharmaceutical manufacturing, the detection of microbial limit failures during routine release testing of active pharmaceutical ingredients (APIs) can…

Leakage Complaint during method transfer: investigation steps with CAPA evidence

Investigating Leakage Complaints during Method Transfer: Key Steps and CAPA Evidence In the landscape of pharmaceutical manufacturing, complaints regarding leakage during method transfer can present significant operational challenges. Such leakage…

Propellant–Formulation Incompatibility after valve supplier change: device qualification and crimp validation controls

Addressing Propellant–Formulation Incompatibility After Valve Supplier Change: A Focused Investigation Approach The pharmaceutical industry is witnessing increased complexity in formulation requirements and device compatibility. A significant issue arises when there…

Delivered Dose Oos in aerosol filling: method variability vs true product failure assessment

Delivered Dose OOS in Aerosol Filling: Evaluating Method Variability vs. True Product Failure The occurrence of Out of Specification (OOS) results in aerosol filling processes presents significant challenges for pharmaceutical…

Spray Pattern Failure during EU/UK distribution qualification: packaging integrity and transport risk assessment

Addressing Spray Pattern Failures in the EU/UK Distribution Qualification of Aerosols In pharmaceutical manufacturing, ensuring the integrity of aerosol products during distribution qualifications is crucial. A recent incident involving a…

API starting material traceability gap during EU GMP inspection preparation: how to justify reprocessing vs rejection to FDA/EMA inspectors

Addressing Gaps in API Starting Material Traceability for EU GMP Inspections In the realm of pharmaceutical manufacturing, ensuring traceability of active pharmaceutical ingredients (APIs) is crucial for regulatory compliance, particularly…

Leakage Complaint during bulk hold: sanitation, water, and EM checks

Investigating Bulk Hold Leakage Complaints in Pharmaceutical Manufacturing In pharmaceutical manufacturing, particularly in the production of otic dosage forms, a leakage complaint during bulk hold can lead to serious compliance…

Valve Malfunction at stability pull: method variability vs true product failure assessment

Assessing Valve Malfunction at Stability Pull: Evaluating Method Variability versus Genuine Product Failure In the realm of pharmaceutical manufacturing, the integrity and reliability of dosage formulation equipment are paramount. One…

Net Content Failure in aerosol filling: FDA/MHRA inspection-ready documentation

How to Investigate Net Content Failure in Aerosol Filling for FDA and MHRA Compliance Net content failures in aerosol filling can pose significant issues in pharmaceutical manufacturing, leading to regulatory…

API container closure compatibility failure during CPV trending review: supplier qualification gaps and incoming testing upgrades to close the loop

Understanding API Container Closure Compatibility Failures During CPV Trending Reviews In pharmaceutical manufacturing, deviations and out-of-specification (OOS) results can arise from various factors, one of which is the compatibility of…

Microbial Limits Failure during bulk hold: manufacturing vs lab root cause decision tree

Investigating Microbial Limits Failures During Bulk Hold: A Comprehensive Decision Tree Approach In the highly regulated world of pharmaceutical manufacturing, microbial limits failures during bulk hold can unravel a well-planned…